Multiple endocrine neoplasia type 1 screening: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
|||
| (23 intermediate revisions by 5 users not shown) | |||
| Line 2: | Line 2: | ||
{{Multiple endocrine neoplasia type 1}} | {{Multiple endocrine neoplasia type 1}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
According to the National Caner Institute, screening for multiple endocrine neoplasia type 1 by imaging studies such as brain [[MRI]], abdominal [[CT]] and abdominal [[MRI]] is recommended every 3-5 year among patients with [[pituitary tumor]]s and [[pancreatic neuroendocrine tumor]]s respectively. Biochemical tests such as serum [[prolactin]], [[insulin-like growth factor]] 1, fasting total serum [[calcium]], ionized [[calcium]], [[parathyroid hormone]], fasting serum [[gastrin]], [[chromogranin A]], [[pancreatic polypeptide]], [[glucagon]] and vaso-intestinal polypeptide are recommended every year among patients with [[pituitary tumor]]s, [[pancreatic neuroendocrine tumor]]s and [[primary hyperparathyroidism]]. | |||
==Screening== | ==Screening== | ||
Screening and surveillance for | Screening and surveillance for multiple endocrine neoplasia type 1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table. <ref name="pmid1677362">{{cite journal| author=Skogseid B, Eriksson B, Lundqvist G, Lörelius LE, Rastad J, Wide L et al.| title=Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 2 | pages= 281-7 | pmid=1677362 | doi=10.1210/jcem-73-2-281 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1677362 }} </ref><ref name="pmid9024241">{{cite journal| author=Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G et al.| title=A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. | journal=J Clin Endocrinol Metab | year= 1997 | volume= 82 | issue= 2 | pages= 486-92 | pmid=9024241 | doi=10.1210/jcem.82.2.3730 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9024241 }} </ref><ref name="pmid9920064">{{cite journal| author=Baudin E, Bidart JM, Rougier P, Lazar V, Ruffié P, Ropers J et al.| title=Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. | journal=J Clin Endocrinol Metab | year= 1999 | volume= 84 | issue= 1 | pages= 69-75 | pmid=9920064 | doi=10.1210/jcem.84.1.5445 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9920064 }} </ref><ref name="pmid19622622">{{cite journal| author=Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S et al.| title=Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 10 | pages= 3640-6 | pmid=19622622 | doi=10.1210/jc.2009-0564 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19622622 }} </ref><ref name="pmid20948872">{{cite journal |vauthors=Falchetti A |title=Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how |journal=F1000 Med Rep |volume=2 |issue= |pages= |year=2010 |pmid=20948872 |pmc=2948394 |doi=10.3410/M2-14 |url=}}</ref> | ||
{|style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align="center" | ||
! style="background:#4479BA; width: 400px" align=center|{{fontcolor|#FFF| Biochemical Test or Procedure}} | ! style="background:#4479BA; width: 400px" align="center" |{{fontcolor|#FFF| Biochemical Test or Procedure}} | ||
! style="background:#4479BA; width: 400px" align=center|{{fontcolor|#FFF| Condition Screened For}} | ! style="background:#4479BA; width: 400px" align="center" |{{fontcolor|#FFF| Condition Screened For}} | ||
! style="background:#4479BA; width: 400px" align=center|{{fontcolor|#FFF| Age Screening Initiated (y)}} | ! style="background:#4479BA; width: 400px" align="center" |{{fontcolor|#FFF| Age Screening Initiated (y)}} | ||
! style="background:#4479BA; width: 400px" align=center|{{fontcolor|#FFF| Frequency}} | ! style="background:#4479BA; width: 400px" align="center" |{{fontcolor|#FFF| Frequency}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Serum prolactin and/or insulin-like growth factor 1 | ! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Serum [[prolactin]]''' and/or [[insulin-like growth factor 1]] | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pituitary tumor]]s | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pituitary tumor]]s | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''5''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''5''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Fasting total serum calcium and/or ionized calcium and parathyroid hormone''' | ! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Fasting total serum [[calcium]] and/or ionized [[calcium]] and [[parathyroid hormone]]''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Parathyroid tumor]]s and [[primary hyperparathyroidism]] | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Parathyroid]][[tumor]]s and [[primary hyperparathyroidism]] | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''8''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''8''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Fasting serum gastrin''' | ! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Fasting serum [[gastrin]]''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|Duodenopancreatic [[gastrinoma]] | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |Duodenopancreatic [[gastrinoma]] | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''20''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''20''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide''' | ! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''[[Chromogranin A]], [[pancreatic polypeptide]], [[glucagon]], and vasointestinal polypeptide''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pancreatic neuroendocrine tumor]]s | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pancreatic neuroendocrine tumor]]s | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''<10years''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''<10years''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Fasting glucose and insulin''' | ! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Fasting [[glucose]] and [[insulin]]''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Insulinoma]] | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Insulinoma]] | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''5''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''5''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Brain MRI''' | ! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Brain [[MRI]]''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pituitary tumor]]s | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pituitary tumor]]s | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left| '''5''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" | '''5''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 3–5 | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 3–5 years based on biochemical results''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Abdominal CT or MRI''' | ! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Abdominal [[CT]] or [[MRI]]''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pancreatic neuroendocrine tumor]]s | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pancreatic neuroendocrine tumor]]s | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''20''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''20''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 3–5 | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 3–5 years based on biochemical results''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Abdominal CT, MRI, or endoscopic US''' | ! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Abdominal [[CT]], [[Magnetic resonance imaging|MRI]], or [[Endoscopic ultrasound|endoscopic US]]''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pancreatic neuroendocrine tumor]]s | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pancreatic neuroendocrine tumor]]s | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''<10''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''<10''' | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year''' | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year''' | ||
|} | |} | ||
| Line 56: | Line 59: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Oncology]] | ||
[[Category:Endocrinology]] | |||
{{WS}} | |||
{{WH}} | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 02:45, 27 November 2017
|
Multiple endocrine neoplasia type 1 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Multiple endocrine neoplasia type 1 screening On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 screening |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the National Caner Institute, screening for multiple endocrine neoplasia type 1 by imaging studies such as brain MRI, abdominal CT and abdominal MRI is recommended every 3-5 year among patients with pituitary tumors and pancreatic neuroendocrine tumors respectively. Biochemical tests such as serum prolactin, insulin-like growth factor 1, fasting total serum calcium, ionized calcium, parathyroid hormone, fasting serum gastrin, chromogranin A, pancreatic polypeptide, glucagon and vaso-intestinal polypeptide are recommended every year among patients with pituitary tumors, pancreatic neuroendocrine tumors and primary hyperparathyroidism.
Screening
Screening and surveillance for multiple endocrine neoplasia type 1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table. [1][2][3][4][5]
| Biochemical Test or Procedure | Condition Screened For | Age Screening Initiated (y) | Frequency |
|---|---|---|---|
| Serum prolactin and/or insulin-like growth factor 1 | Pituitary tumors | 5 | Every 1 year |
| Fasting total serum calcium and/or ionized calcium and parathyroid hormone | Parathyroidtumors and primary hyperparathyroidism | 8 | Every 1 year |
| Fasting serum gastrin | Duodenopancreatic gastrinoma | 20 | Every 1 year |
| Chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide | Pancreatic neuroendocrine tumors | <10years | Every 1 year |
| Fasting glucose and insulin | Insulinoma | 5 | Every 1 year |
| Brain MRI | Pituitary tumors | 5 | Every 3–5 years based on biochemical results |
| Abdominal CT or MRI | Pancreatic neuroendocrine tumors | 20 | Every 3–5 years based on biochemical results |
| Abdominal CT, MRI, or endoscopic US | Pancreatic neuroendocrine tumors | <10 | Every 1 year |
References
- ↑ Skogseid B, Eriksson B, Lundqvist G, Lörelius LE, Rastad J, Wide L; et al. (1991). "Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds". J Clin Endocrinol Metab. 73 (2): 281–7. doi:10.1210/jcem-73-2-281. PMID 1677362.
- ↑ Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G; et al. (1997). "A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13". J Clin Endocrinol Metab. 82 (2): 486–92. doi:10.1210/jcem.82.2.3730. PMID 9024241.
- ↑ Baudin E, Bidart JM, Rougier P, Lazar V, Ruffié P, Ropers J; et al. (1999). "Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors". J Clin Endocrinol Metab. 84 (1): 69–75. doi:10.1210/jcem.84.1.5445. PMID 9920064.
- ↑ Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S; et al. (2009). "Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors". J Clin Endocrinol Metab. 94 (10): 3640–6. doi:10.1210/jc.2009-0564. PMID 19622622.
- ↑ Falchetti A (2010). "Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how". F1000 Med Rep. 2. doi:10.3410/M2-14. PMC 2948394. PMID 20948872.